Related content

Clinical usefulness of AGEs as a biomarker for the attenuation of NASH

By Tasci Ilker  

Journal of Gastroenterology, Vol. 45, Iss. 7, 2010-07 ,pp. : 779-780

Springer Publishing Company

Access to resources Recommend Favorite

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

By Kimura Yuki   Hyogo Hideyuki   Yamagishi Sho-ichi   Takeuchi Masayoshi   Ishitobi Tomokazu   Nabeshima Yoshitaka   Arihiro Koji   Chayama Kazuaki  

Journal of Gastroenterology, Vol. 45, Iss. 7, 2010-07 ,pp. : 750-757

Springer Publishing Company

Access to resources Recommend Favorite

Reply to the letter by Y. Yilmaz regarding ‘‘the AGEs–RAGE axis and nonalcoholic steatohepatitis’’

By Hyogo Hideyuki  

Journal of Gastroenterology, Vol. 45, Iss. 7, 2010-07 ,pp. : 784-784

Springer Publishing Company

Access to resources Recommend Favorite

Caveats regarding the use of HbA 1c for prediction of mean blood glucose. Reply to Chalew S, Hempe JM [letter]

By Nathan D.  

Diabetologia, Vol. 51, Iss. 5, 2008-05 ,pp. : 905-906

Springer Publishing Company

Access to resources Recommend Favorite

Reply to letter from Sebastian F. Schoppmann et al. regarding `Radial esophageal acid exposure and the dilated distal esophagus'

By Ohara Shunji  

Journal of Gastroenterology, Vol. 47, Iss. 11, 2012-11 ,pp. : 1277-1278

Springer Publishing Company

Access to resources Recommend Favorite